RUIXUN Biotech Secures Tens of Millions of RMB in Series C2 Strategic Financing to Advance Digital PCR and mRNA LNP Platforms

VCBeat has learned that in December 2024, Suzhou RainSure Scientific Co., Ltd. (“RainSure Scientific”) recently completed a strategic financing round of tens of millions of RMB in its C2 series. The round was led byRuijiang KangshengLead investor. The funds raised will be used for domestic and international clinical registration of digital PCR products, expansion into the European market, and new product development, providing strong support for RainSure SCIENTIFIC to maintain its leading position in the fields of digital PCR and mRNA LNP. Through this financing round, RainSure SCIENTIFIC will also establish a strategic partnership with Kangsheng Global Group, with in-depth collaboration in areas such as joint product development, hospital admission of domestic clinical products, and overseas product sales.

As one of the leading domestic enterprises in digital PCR and mRNA LNP technologies, RainSure SCIENTIFIC remains committed to the independent development of key core technologies. Its products have been granted multiple invention patents both domestically and internationally. RainSure’s digital PCR products rank among the top three Chinese brands in terms of domestic market share and hold a leading position among Chinese brands in overseas markets. These systems are installed in China’s top-tier tertiary hospitals, prestigious academic institutions, and industry-leading enterprises. The company’s mRNA LNP products serve globally renowned research-intensive universities such as Harvard, Stanford, MIT, Yale, and Tsinghua University; government laboratories including NASA, the FDA, and the NIH; and prominent pharmaceutical companies such as Gilead and Regeneron. Among Chinese mRNA LNP brands, RainSure holds a leading share in the overseas market.

Drop-Series Digital PCR System

RS32 Series Fully Automated Digital PCR System

mRNA LNP Product Line

Currently, RainSure SCIENTIFIC’s products are sold in over 30 countries and regions, with nearly 200 publications by global customers citing its products, accumulating a total impact factor of more than 2,000. This demonstrates the international recognition of high-end medical devices made in China. Moving forward, RainSure SCIENTIFIC will continue to complete the NMPA and FDA registration submissions for several digital PCR products. Its mRNA LNP products will be actively expanded to large pharmaceutical company clients.

For this round of financing,Zhao Jinqiang, Chairman of Ruijiang KangshengMr. [Name] stated, “We are delighted to partner with RainSure SCIENTIFIC. As a leading enterprise in the field of digital PCR (dPCR) in China, RainSure SCIENTIFIC is highly regarded by Hubei Ruijiang Kangsheng Industrial Investment Fund Partnership (Limited Partnership) for the future applications of dPCR in scientific research, industry, and clinical settings. We affirm that dPCR technology represents the future direction of nucleic acid molecular technologies. With strong technical accumulation, RainSure SCIENTIFIC has demonstrated significant momentum in product development, independent innovation, and regulatory submissions, positioning this phase as a key inflection point for its performance growth. Furthermore, RainSure SCIENTIFIC’s global strategy places it at the forefront and in a leading position within its niche sector. Its dPCR products will complement KingMed Diagnostics’ clinical portfolio, leveraging KingMed’s robust sales network to achieve mutual success. In the realm of mRNA-LNP-based nucleic acid therapeutics, which is poised to be a major developmental focus over the next 5–10 years, numerous international companies are actively investing in mRNA vaccines and anti-tumor drugs. RainSure SCIENTIFIC’s products provide essential tools for this segment of the supply chain. Looking ahead, RainSure SCIENTIFIC is destined to become a globally influential leader in the upstream sectors of life sciences and clinical diagnostics.”

Dr. Wang Yaqi, Chairman of RainSure SCIENTIFICstated: “We are honored to receive investment from the Ruijiang Kangsheng Fund in this financing round, and we are also pleased to seize this opportunity to establish a partnership with HealthGene Group. Driven by this round of financing, we remain committed to continuous innovation as our foundation, aiming to develop and manufacture products at a globally advanced level, further expand the market share of our domestic products, and continue to deepen our presence in the fields of digital PCR and mRNA LNP nucleic acid vaccine therapeutics.”

RainSure SCIENTIFIC was established in July 2017 and is recognized as a National High-Tech Enterprise. The company has received numerous honors, including being named a Leading Enterprise in Technological Innovation and Entrepreneurship in the Industrial Park (2018), inclusion in the Gusu Sci-Tech Entrepreneurship Angel Plan (2019), designation as a Potential Unicorn Enterprise of Jiangsu Province, selection for the Key R&D Program of Jiangsu Province, and accreditation as a Suzhou Engineering Technology Research Center. Additional accolades include the 2019 Award for Excellent New Scientific Instrument Products; recognition in 2020 as an Innovative Product for Combating the Novel Coronavirus Epidemic in Suzhou Industrial Park for its Novel Coronavirus Nucleic Acid Detection Kit and Supporting Equipment (Digital PCR Method); the Bronze Award in the Anti-COVID-19 Category at the 1st Medical Science and Technology Innovation Competition (2020); designation as an Excellent Project at the National Disruptive Technology Innovation Competition (2021); and the Excellent Project Award at the Suzhou “Maker’s Paradise” event (2021). In November 2021, RainSure SCIENTIFIC jointly drafted with the Jiangsu Center for Disease Control and Prevention the first local industry standard for digital PCR, which was prominently released: “Technical Specifications for Novel Coronavirus Detection – Part 16: Nucleic Acid Digital PCR Method.”

The company has currently obtained four Class II medical device registration certificates. Two products with Class III medical device registration certificates are in the clinical trial phase, with NMPA Class III certification and FDA 510(k) clearance expected to be approved in 2025.

Ruijiang Investment was established in 2012, with its headquarters in Wuhan and branches and teams in Beijing, Shanghai, and Shenzhen. The company’s vision is to meet people’s needs for a better life through high-quality financial services and products. Its core business covers the management of equity investment funds and industrial investment funds. Discovering value and creating value, while partnering with outstanding entrepreneurs, has always been our consistent philosophy. The company’s founder graduated from the University of Chicago, and its management and investment teams consist of seasoned investment professionals with an international perspective. The company manages ten equity investment funds, with past limited partners (LPs) including fund-of-funds, family offices, and listed companies. Ruijiang Investment has been ranked among the Top 20 venture capital firms in China’s healthcare sector. Wuhan Ruijiang Kangsheng Venture Capital Fund Partnership (Limited Partnership) is a venture capital fund jointly established by Ruijiang Investment, the listed company Kangsheng Global, the well-known state-owned Wuhan Industrial Fund, and Optics Valley Financial Holdings, focusing on investments in the healthcare and biopharmaceutical sectors.